News brief­ing: CG On­col­o­gy nets $47M Se­ries D for blad­der can­cer stud­ies; Sin­gle-cell tran­scrip­tom­ic start­up rais­es $24M launch cash

CG On­col­o­gy has some new cash to play with.

The Irvine, CA-based biotech an­nounced Thurs­day it closed a $47 mil­lion Se­ries D round of pre­ferred stock fi­nanc­ing as the com­pa­ny con­tin­ues to ad­vance late-stage tri­als for its lead pro­gram, CG0070. With the mon­ey, CG ex­pects to fund an on­go­ing Phase III study in non-mus­cle in­va­sive blad­der can­cer as a monother­a­py, as well as a com­bo Phase II tri­al with Mer­ck’s Keytru­da.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.